Biohaven Ltd. (BHVN)
15.29
+0.81
(+5.59%)
USD |
NYSE |
Nov 09, 11:58
Biohaven Total Liabilities (Quarterly) : 361.92M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 361.92M |
| June 30, 2026 | 358.52M |
| March 31, 2026 | 336.91M |
| December 31, 2025 | 399.38M |
| September 30, 2025 | 426.28M |
| June 30, 2025 | 415.83M |
| March 31, 2025 | 199.45M |
| December 31, 2024 | 191.67M |
| September 30, 2024 | 194.52M |
| Date | Value |
|---|---|
| June 30, 2024 | 198.90M |
| March 31, 2024 | 117.08M |
| December 31, 2023 | 85.24M |
| September 30, 2023 | 92.73M |
| June 30, 2023 | 119.48M |
| March 31, 2023 | 146.26M |
| December 31, 2022 | 123.01M |
| September 30, 2022 | 35.43M |
| June 30, 2022 | 73.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| NovelStem International Corp. | 2.097M |
| Brainstorm Cell Therapeutics, Inc. | 12.38M |
| Summit Therapeutics, Inc. | 128.17M |
| Kezar Life Sciences, Inc. | 2.762M |
| Protara Therapeutics, Inc. | 15.52M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 263.68M |
| Shareholders Equity (Quarterly) | -98.25M |
| Debt to Equity Ratio | -3.058 |
| Current Ratio | 3.051 |
| Net Debt Paydown Yield | -0.09% |